Tag:
Genzyme
Latest Headlines
Latest Headlines
As Shire gives up on Replagal in U.S., Sanofi stands to gain
Sanofi ( $SNY ) may want to thank its lucky stars that its new Genzyme plant won FDA approval when it did. The facility in Framingham, MA, will allow the French drugmaker's rare-disease unit to get back on track with its Fabry disease drug Fabrazyme . It may also have deterred Shire from pursuing its own Fabry drug application in the face of complications at the FDA.
Sanofi cuts continue with closing of manufacturing plant in U.K.
Sanofi ( $SNY ), which has spent the last year trimming manufacturing and R&D operations around the globe, has taken aim at another U.K. facility.
Litigation: Sanofi, Genzyme 'negligently allowed a virus contamination in the manufacturing facility'
Litigation is testing whether manufacturing problems at a pharmaceutical plant that led to a drug shortage can be considered legal negligence--as well as whether the manufacturer can be held accountable for patients' deaths.
Lilly outlines $442M Ireland plans
Eli Lilly ( $LLY ) says it will invest €330 million in its previously announced expansion at its Kinsale campus in Ireland. Work is beginning at the 240,000-square-foot commercialization and...
Sanofi slams doors on Genzyme's Cambridge, U.K., outfit
As part of an ongoing restructuring effort, Sanofi ( $SNY ) is shuttering Genzyme 's Cambridge, U.K., R&D operation by the end of the year.
Shire's $200 million LEED-certified plant gets EMA nod
With European approval, Shire ( $SHPGY ) is ready to start production at its new $200 million, energy efficient plant in Lexington, MA. The EMA has given the biopharmaceutical company the green light...
Shire to boost Vpriv, Replagal with EMA-approved plant
Shire 's rare-disease challenge is heating up.
Sanofi yanks drug batch on CMO contamination fears
Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ( $SNY ) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380
Sanofi touts R&D hopefuls as tonic for plunging profits
This is the year that the patent cliff arrives with a vengeance at Sanofi ( $SNY ). With copycat versions of Plavix and Avapro gobbling market share, the pharma giant predicted a 15% plunge in profits
Sanofi CEO: Look out below, profits are falling
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
